Juan M. Moron-Vazquez

Huelva, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry.

Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: March 31, 2025

Effectiveness and safety of ustekinumab dose escalation in Crohn's disease: a multicenter observational study.

Effectiveness and safety of ustekinumab dose escalation in Crohn's disease: a multicenter observational study.

Journal: Revista espanola de enfermedades digestivas

Published: June 14, 2023

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.

Journal: The American journal of gastroenterology

Published: July 13, 2022

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.

Journal: Journal of clinical medicine

Published: June 10, 2022

Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia.

Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia.

Journal: Revista espanola de enfermedades digestivas

Published: January 10, 2022

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.

Journal: Inflammatory bowel diseases

Published: September 10, 2021

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.

Journal: Revista espanola de enfermedades digestivas

Published: January 04, 2021

Intravenous ustekinumab reinduction as a Crohn's disease rescue strategy following a secondary non-response.

Intravenous ustekinumab reinduction as a Crohn's disease rescue strategy following a secondary non-response.

Journal: Revista espanola de enfermedades digestivas

Published: July 24, 2019

The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

Journal: Revista espanola de enfermedades digestivas

Published: July 24, 2019

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: April 13, 2019

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.

Journal: Revista espanola de enfermedades digestivas

Published: June 13, 2018

Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the "Gestiona hierro-EII" survey.

Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the "Gestiona hierro-EII" survey.

Journal: Revista espanola de enfermedades digestivas

Published: February 22, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026